Dr. Conrad Winters has been appointed director of drug product development at Hovione. Dr. Winters was previously with Merck in the U.S. and Canada and most recently with Xenon Pharmaceuticals, where he served as senior director of Compound Properties Group.
 
“We are very pleased to welcome Dr. Winters to Hovione. His experience in particle engineering, solubilization, drug product development, scale up and commercialization will enable us to solve our customers’ most challenging problems,” said Dr. Thomas Eisele, vice president Corporate R&D.
 
Dr. Winters has 18 years of experience in the pharmaceutical industry with a focus on managing the development of compounds from lead candidate optimization through to NDA submission and commercialization. Dr. Winters has led global teams charged with the development of priority new chemical entities and has contributed to and prepared many successful regulatory submissions.